Treatment strategies in Rett syndrome so far have been essentially symptomatic and supportive. In order to establish the medium-term effects of L-carnitine, an open label trial was performed in a cohort of 21 Rett syndrome females, with a control group of 62 Rett syndrome females of a similar age, for a 6-month period. Compared with the Rett syndrome controls, treatment with L-carnitine led to significant improvements in sleep efficiency (P=0.027), especially in the subjects with a baseline sleep efficiency less than 90%, energy level (P<0.005) and communication skills (P=0.004). There was no significant difference in the subject's level of physical activity, hand function or in the quality of life of the subject's parents. In addition, before and after comparisons of the treatment group showed improvements in expressive speech (P=0.011). Treatment with L-carnitine seems to be of significant benefit in a subgroup of girls with Rett syndrome. In these girls, small but discernible improvements may be of considerable importance to their parents and carers.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Brain and Development
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Rett syndrome: randomised controlled trial of L-carnitine.J Child Neurol. 1999; 14: 162-167
- The prevalence and incidence of Rett syndrome in Australia.Eur Child Adolesc Psychiatry. 1997; 6: 8-10
Ellaway CJ, Peat J, Christodoulou J. Development of the Rett syndrome: symptom index score. World Congress on Rett Syndrome Karuizawa, Japan, July, 2000.
- The hand apraxia scale.Percept Mot Skills. 1990; 70: 219-224
- Evaluation of commercial accelerometer (Tritrac-R3D) to measure energy expenditure during ambulation.Int J Sports Med. 1998; 19: 43-47
- SF-36 health survey manual and interpretation guide. The Health Institute, New England Medical Center, Boston, MA1993
- First prenatal diagnosis of the carnitine transporter defect.Am J Med Genet. 1996; 66: 21-24
- Carnitine deficiency states.Pediatr Neurol. 1990; 6: 75-81
- Energy on demand.Science. 1999; 283: 496-497
© 2001 Elsevier Science B.V. Published by Elsevier Inc. All rights reserved.